RayKnowChina Research Map
Shortlist

SuzhouSoochow University

Second Affiliated Hospital of Soochow University

苏州大学附属第二医院

Listed for 12 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Second Affiliated Hospital of Soochow University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌5 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
  3. Stomach cancer胃癌32 papers led
  4. Osteosarcoma骨肉瘤12 papers led
  5. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  6. Ewing sarcoma尤文肉瘤1 paper led
  7. Multiple myeloma多发性骨髓瘤2 papers led
  8. Fabry disease法布雷病0 papers led
  9. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  10. Behçet disease白塞病1 paper led
  11. IgA nephropathyIgA 肾病1 paper led
  12. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led

Not listed for: Hepatocellular carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 2220242025: 112025

2 hospitals in Suzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueInduction / concurrent chemotherapyImaging & AI
Departments in papersRadiation oncologyGastroenterology / hepatologyENT / head & neck surgeryNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025

3 hospitals in Suzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & AIMolecular markers & genomicsSurgery
Departments in papersMedical oncologyRadiation oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 32 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
32
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 5520212022: 4420222023: 101020232024: 8820242025: 552025

3 hospitals in Suzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07552402

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan

  2. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryPeritoneal spread & advanced diseaseNutrition & recovery
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyRadiation oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led32
  1. Machine learning models for prediction of lymph node metastasis in patients with gastric cancer: a Chinese single-centre study with external validation in an Asian American population.2025BMJ openFree full text
  2. Development and current status of anti-reflux esophagogastrostomy after proximal gastrectomy: a literature review.2025Langenbeck's archives of surgeryFree full text
  3. Development and Characterization of the [177Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model.2025Molecular pharmaceuticsFree full text
  4. Postoperative hypotension in gastric cancer patients: causes and clinical approaches.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  5. Metabolic regulation of amino acids provides an important basis for individualized nutritional therapy for patients with gastric cancer during the perioperative period.2025World journal of surgical oncologyFree full text
  6. Incidence and risk of remnant gastric cancer after gastrectomy for gastric cancer: a population-based study from the SEER database.2024BMC gastroenterologyFree full text
  7. A case-series study of hepatic left lateral segment inversion for surgical field exposure in laparoscopic gastrectomy.2024BMC surgeryFree full text
  8. Tumor-derived Prevotella intermedia aggravates gastric cancer by enhancing Perilipin 3 expression.2024Cancer scienceFree full text
  9. DDX24 promotes tumor progression by mediating hexokinase-1 induced glycolysis in gastric cancer.2024Cellular signalling
  10. MiR-30a-5p isoform -1|1 promotes the progression of gastric cancer by inhibiting TMEM66 and reducing intratumoral cytotoxic T cells.2024Experimental cell research
  11. Investigating MATN3 and ASPN as novel drivers of gastric cancer progression via EMT pathways.2024Human molecular genetics
  12. CircFNTA promotes tumorigenesis and progression of gastric cancer via miR-604/miR-647/SCN8A axis.2024Journal of biochemical and molecular toxicology
  13. The relationship between splenic dose and radiation-induced lymphopenia.2024Journal of radiation researchFree full text
  14. RAI2 acts as a tumor suppressor with functional significance in gastric cancer.2023AgingFree full text
  15. High expression of serine protease 2 (PRSS2) associated with invasion, metastasis, and proliferation in gastric cancer.2023AgingFree full text
  16. Decreased KLF3 Expression via miR-660-5p Targeting Suppresses Gastric Cancer Cell Progression.2023Annals of clinical and laboratory science
  17. METTL3 regulates N6-methyladenosine modification of ANGPTL3 mRNA and potentiates malignant progression of stomach adenocarcinoma.2023BMC gastroenterologyFree full text
  18. Peripheral CD4+CD25hiCD127low regulatory T cells are increased in patients with gastrointestinal cancer.2023BMC gastroenterologyFree full text
  19. Laparoscopic proximal gastrectomy with right-sided overlap and single-flap valvuloplasty (ROSF): a case-series study.2023BMC surgeryFree full text
  20. Development and validation of a multiphase CT radiomics nomogram for the preoperative prediction of lymphovascular invasion in patients with gastric cancer.2023Clinical radiology
  21. Exosomal circ_0091741 promotes gastric cancer cell autophagy and chemoresistance via the miR-330-3p/TRIM14/Dvl2/Wnt/β-catenin axis.2023Human cell
  22. MST4 as a novel therapeutic target for autophagy and radiosensitivity in gastric cancer.2023IUBMB life
  23. Targeting ROR1 inhibits glucocorticoid-induced gastric cancer growth.2023Steroids
  24. Inhibition of Musashi-1 enhances chemotherapeutic sensitivity in gastric cancer patient-derived xenografts.2022Experimental biology and medicine (Maywood, N.J.)Free full text
  25. PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report.2022Frontiers in immunologyFree full text
  26. Current status of internal hernia after gastrectomy for gastric cancer.2022Langenbeck's archives of surgery
  27. Clinicopathological Analysis and Prognostic Assessment of TCN1 in Patients with Gastric Cancer.2022Surgical innovation
  28. Current status of laparoscopic proximal gastrectomy in proximal gastric cancer: Technical details and oncologic outcomes.2021Asian journal of surgery
  29. TYMSOS drives the proliferation, migration, and invasion of gastric cancer cells by regulating ZNF703 via sponging miR-4739.2021Cell biology international
  30. Mast1 mediates radiation-induced gastric injury via the P38 MAPK pathway.2021Experimental cell research
  31. Esophagus two-step-cut overlap method in esophagojejunostomy after laparoscopic gastrectomy.2021Langenbeck's archives of surgery
  32. UFBP1, a key component in ufmylation, enhances drug sensitivity by promoting proteasomal degradation of oxidative stress-response transcription factor Nrf2.2021Oncogene
Chinese-language papers (not in the count)4
  1. [Application status of vagus nerve preservation and double-flap technique in laparoscopic proximal gastrectomy].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Artificial intelligence for lymph node metastasis prediction in gastric cancer: research progress].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [A preliminary exploration of reduced port laparoscopic proximal gastrectomy with right-sided overlap and single-flap valvuloplasty (ROSF)].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Immune-Related Pancreatitis Caused by Immune Checkpoint Inhibitor Nivolumab:Report of One Case].2023Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
All its trials on ClinicalTrials.gov, any status10
  1. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNCT07552402Study siteN/AStart 2026-06
  2. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  3. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  4. HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese PatientsStatus unknownNCT05526339Study siteN/AStart 2022-09
  5. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  6. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  7. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  8. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  9. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  10. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center StudyStatus unknownNCT03121729Study siteN/AStart 2017-06

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 12 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 1120232024: 2220242025: 112025

16 hospitals in Suzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryMedical oncology

Over half of these papers are lab or animal studies.

Papers it led12
  1. STUB1-mediated ubiquitination of SLC25A10 regulates mitochondrial function and drives osteosarcoma progression: A novel therapeutic target.2025Cellular signalling
  2. KAT7 serves as an oncogenic gene and regulates CCL3 expression via STAT1 signaling in osteosarcoma.2024Biochemical and biophysical research communications
  3. Mitochondria targeted biomimetic platform for chemo/photodynamic combination therapy against osteosarcoma.2024International journal of pharmaceutics
  4. A Feedback Loop of LINC00665 and the Wnt Signaling Pathway Expedites Osteosarcoma Cell Proliferation, Invasion, and Epithelial-Mesenchymal Transition.2023Orthopaedic surgery
  5. ADCK1 is a potential therapeutic target of osteosarcoma.2022Cell death & disease
  6. Identification of Gαi3 as a promising target for osteosarcoma treatment.2022International journal of biological sciences
  7. Gliosarcoma with osteosarcomatous component: A case report and short review illustration.2022Pathology, research and practice
  8. LncRNA LOC100129620 promotes osteosarcoma progression through regulating CDK6 expression, tumor angiogenesis, and macrophage polarization.2021Aging
  9. COL3A1 and Its Related Molecules as Potential Biomarkers in the Development of Human Ewing's Sarcoma.2021BioMed research international
  10. ARHGEF3 Associated with Invasion, Metastasis, and Proliferation in Human Osteosarcoma.2021BioMed research international
  11. miRNA-296-5p functions as a potential tumor suppressor in human osteosarcoma by targeting SND1.2021Chinese medical journal
  12. Propofol suppresses osteosarcoma cell function by regulating FOXO1/TUSC7.2021The Journal of pharmacy and pharmacology
Earlier papers (2016–2020)7
  1. MicroRNA-187 suppresses the proliferation migration and invasion of human osteosarcoma cells by targeting MAPK7.2020Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  2. High Expression of N-Acetylgalactosaminyl-transferase 1 (GALNT1) Associated with Invasion, Metastasis, and Proliferation in Osteosarcoma.2020Medical science monitor : international medical journal of experimental and clinical research
  3. Proliferation inhibition and apoptosis promotion by dual silencing of VEGF and Survivin in human osteosarcoma.2019Acta biochimica et biophysica Sinica
  4. EP1 receptor is involved in prostaglandin E2-induced osteosarcoma growth.2019Bosnian journal of basic medical sciences
  5. MiR-299-5p targets cell cycle to promote cell proliferation and progression of osteosarcoma.2018European review for medical and pharmacological sciences
  6. The anti-tumor effect of pachymic acid on osteosarcoma cells by inducing PTEN and Caspase 3/7-dependent apoptosis.2018Journal of natural medicines
  7. miR-29 Family Inhibits Resistance to Methotrexate and Promotes Cell Apoptosis by Targeting COL3A1 and MCL1 in Osteosarcoma.2018Medical science monitor : international medical journal of experimental and clinical research

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

6 hospitals in Suzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Suzhou for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.

Papers led
2
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

2 hospitals in Suzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Recruiting
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07179679

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an

  3. Recruiting
    UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2024-04
    Registry
    NCT06279026

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteSuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDrug combinations
Papers it led2
  1. Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosis.2024Apoptosis : an international journal on programmed cell death
  2. Anti-BCMA-engineered exosomes for bortezomib-targeted delivery in multiple myeloma.2024Blood advancesFree full text
Chinese-language papers (not in the count)5
  1. [The Role and Possible Mechanism of T Cell Costimulatory Molecule CD28 Activation in Pathogenesis of Multiple Myeloma].2025Zhongguo shi yan xue ye xue za zhi
  2. [The Impact of SRSF1 -Mediated Alternative Splicing of RBBP6 on the Proliferation of Multiple Myeloma Cells].2024Zhongguo shi yan xue ye xue za zhi
  3. [Bone Marrow Adipocytes Promote the Survival of Multiple Myeloma Cells and Up-Regulate Their Chemoresistance].2023Zhongguo shi yan xue ye xue za zhi
  4. [Clinical Significance of CD28 Expression in Newly Diagnosed Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  5. [Effect of the Connexin 43 Coupling to the Biobehavior of Multiple Myeloma Cells].2021Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status6
  1. Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed/Refractory Multiple MyelomaStatus unknownNCT05857982Lead sponsorPhase 1/Phase 2Start 2023-05
  2. Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple MyelomaStatus unknownNCT02027220Lead sponsorPhase 2Start 2013-12
  3. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  4. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Study sitePhase 1Start 2025-12
  5. UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT06279026Study siteN/AStart 2024-04
  6. A Clinical Trial of TQB2934 for Injection in Multiple Myeloma SubjectsStatus unknownNCT05646758Study sitePhase 1Start 2023-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Suzhou for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Suzhou for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Suzhou for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)
Papers it led1
  1. Identification of biomarkers for abdominal aortic aneurysm in Behçet's disease via mendelian randomization and integrated bioinformatics analyses.2024Journal of cellular and molecular medicine
Earlier papers (2016–2020)1
  1. [Progress in interferon: A treatment of Behcet syndrome].2020Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

7 hospitals in Suzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Suzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic InjuryCompletedNCT06888115Study sitePhase 1Start 2025-03

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

苏州大学附属第二医院

Second Affiliated Hospital of Soochow University

苏州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Second Affiliated Hospital of SooChow University; General Hospital of Nuclear Industry; Sino-France Friendship Hospital

Suggest a correctionDownload the data